ResMed Inc is a global leader in digital health and cloud-connected devices that serve individuals with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic respiratory conditions. The company specializes in creating innovative solutions that improve the quality of life for patients through advanced technology, including ventilators, sleep therapy devices, and patient monitoring systems. By leveraging data analytics and machine learning, ResMed enhances patient engagement and treatment adherence, thereby promoting better health outcomes. The company's commitment to research and development allows it to continuously advance its portfolio, making a significant impact on the healthcare landscape. Read More
Medical device company ResMed (NYSE:RMD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 10.2% year on year to $1.35 billion. Its non-GAAP profit of $2.55 per share was 3% above analysts’ consensus estimates.
ResMed trades at $254.11 per share and has stayed right on track with the overall market, gaining 8.9% over the last six months. At the same time, the S&P 500 has returned 5.4%.
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
RESMED INC (NYSE:RMD) is a high-quality stock with strong revenue growth, exceptional ROIC, and solid cash flow, making it a standout pick for long-term investors.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
RESMED INC (NYSE:RMD) is a high-quality stock with strong profitability, low debt, and consistent growth, making it a candidate for long-term investors.
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.
However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
Companies with more cash than debt often have stronger financial flexibility, making them attractive in uncertain markets.
Without interest payments being less of a worry, these businesses can invest more in growth, innovation, or buybacks and dividends.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 13.2%. This performance was significantly worse than the S&P 500’s 2.4% decline.
Exciting developments are taking place for the stocks in this article.
They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
Wall Street has issued downbeat forecasts for the stocks in this article.
These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
RESMED INC (NYSE:RMD) is a high-quality stock with strong revenue growth, exceptional profitability, and a solid balance sheet, making it a standout pick for long-term investors.
